Interaction between pre-treatment drug use and heterogeneity of psychiatric diagnosis predicts outcomes in outpatients with co-occurring disorders
Interaction between pre-treatment drug use and heterogeneity of psychiatric diagnosis predicts outcomes in outpatients with co-occurring disorders
复制标题
DOI：
10.1016/j.psychres.2017.11.070
复制
发表时间：
2018-02-01
影响因子：
11.3
通讯作者：
McDonell, Michael G.
中科院分区：
文献类型：
--
作者：
Oluwoye, Oladunni;Hirchak, Katherine;McDonell, Michael G.
我们研究了基线兴奋剂使用的相互作用，通过尿液药物测试评估，和严重精神疾病（SMI）诊断的类型预测兴奋剂使用的应急管理（CM）试验。当控制治疗条件、基线兴奋剂使用和SMI诊断的主要影响时，基线兴奋剂使用和SMI诊断之间的相互作用在总体样本中是显著的（p =0.002）。在CM样品中也发现了类似的结果。与其他SMI诊断相比，双相情感障碍患者在治疗期间使用兴奋剂的可能性更大或更小，这取决于他们的基线兴奋剂药物测试结果。
We examined whether the interaction of baseline stimulant use, assessed by urine drug tests, and type of serious mental illness (SMI) diagnosis predicted stimulant use in a trial of contingency management (CM). The interaction between baseline stimulant use and SMI diagnoses was significant in the overall sample (p =0.002) when controlling for the main effects of treatment condition, baseline stimulant use, and SMI diagnosis. Similar results were also found within the CM sample. Individuals with bipolar disorder were more or less likely, depending on their baseline stimulant-drug test results, to use stimulants during treatment compared to those with other SMI diagnoses.